Herantis Pharma
CompanyFinlandFounded 2008
Herantis Pharma develops 3 assets, the furthest in phase 2 (cis-UCA in dry eye syndrome). Mostly small molecule and protein or enzyme acting on inflammation, proteostasis and CDNF; based in Finland, founded in 2008.
- 3
- Assets
- Furthest
- Phase 2
- 4
- Trials
- 0
- Signals
Pipeline
3Cis-urocanic acid anti-inflammatory modulator for ocular surface indications.
Phase 2, Small molecule, Inflammation, dry eye syndrome
Cerebral Dopamine Neurotrophic Factor
Neurotrophic factor alleviating endoplasmic reticulum stress and promoting dopamine neuron survival.
Phase 1, Protein or enzyme, Proteostasis, Inflammation, brain diseases, movement disorders
CDNF peptidomimetic alleviating proteostatic stress and supporting dopaminergic neuron survival.
Phase 1, Peptide, Proteostasis, Inflammation, idiopathic Parkinson disease
Full company profiles: pipeline, trials, funding and people.
See ProIn the full profile
- Evidence behind the mechanisms2
- Trials4
- Similar companies6
Updated 8 Oct 2026 · 11 sources